Microbial flora in NSAID-induced intestinal damage: A role for antibiotics?

Digestion

Volumn 73, Issue SUPPL. 1, 2006, Pages 136-150

  Lanas, Ángel ^a   Scarpignato, Carmelo ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

Antibiotics; GI system; NSAID enteropathy; NSAID gastropathy; NSAIDs; Rifaximin; Selective COX 2 inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; CALPROTECTIN; CELECOXIB; CHLORTALIDONE; CIMETIDINE; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DOXAZOSIN; ETODOLAC; FAMOTIDINE; FENAMIC ACID DERIVATIVE; IBUPROFEN; INDOMETACIN; KETOPROFEN; LUMIRACOXIB; MEFENAMIC ACID; MELOXICAM; NABUMETONE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PIROXICAM; RIFAXIMIN; ROFECOXIB; SUCRALFATE; SULINDAC; UNINDEXED DRUG; VALDECOXIB;

ACUTE DIARRHEA; ACUTE HEART INFARCTION; ANEMIA; ANGIODYSPLASIA; ATROPHY; BACTERIAL TRANSLOCATION; BLEEDING; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL TRIAL; COLITIS; COLON ULCER; CONGESTIVE HEART FAILURE; DIAPHRAGM DISEASE; DIARRHEA; DIVERTICULOSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COATING; DRUG FORMULATION; DRUG MEGADOSE; DRUG RELEASE; DRUG TOLERABILITY; ENTERITIS; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART PROTECTION; HUMAN; HYPERTENSION; HYPOALBUMINEMIA; ILEUM DYSFUNCTION; INTESTINE FLORA; INTESTINE INJURY; INTESTINE MUCOSA PERMEABILITY; INTESTINE PERFORATION; INTESTINE ULCER; IRON DEFICIENCY ANEMIA; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MALABSORPTION; MUCOSA INFLAMMATION; NEPHROTOXICITY; NONHUMAN; OCCULT BLOOD; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEPLETION; RECTUM ULCER; REVIEW; RISK FACTOR; SIDE EFFECT; STROKE; SUDDEN DEATH; THROMBOSIS;

ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; INTESTINAL DISEASES; INTESTINAL MUCOSA; RISK FACTORS; ULCER;

EID: 33644531928     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089789     Document Type: Review

References (132)

1. Lanas A: NSAIDs and ulcer disease: scope of the problem, NSAIDS vs. COX-2 selective inhibitors, role of PPIs, risk factors and strategies for management. Post J Med 2005;117:23-28.
2. Scarpignato C, Bjarnason I, Bretagne JF, De Pouvourville G, García Rodríquez LA, Goldstein JL, Müller P A, Simon B: Working Team Report: Towards a GI safer antiinflammatory therapy. Gastroenterol Int 1999;12:186-215.
3. Scarpignato C: Nonsteroidal anti-inflammatory drugs: how do they damage gastroduodenal mucosa? Dig Dis 1995;13(suppl 1):9-39.
4. Houchen CW: Clinical implications of prostaglandin inhibition in the small bowel. Gastroenterol Clin North Am 2001;4:953-969.
5. Lanas A, Panés J, Pique JM: Clinical implications of COX-1 and/or COX-2 inhibition for the distal gastrointestinal tract. Curr Pharm Des 2003;9:2253-2266.
6. Fortun PJ, Hawkey CJ: Nonsteroidal anti-inflammatory drugs and the small intestine. Curr Opin Gastroenterol 2005;21:169-175.
7. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, VIGOR Study Group: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-1528.
8. Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Matchaba P, Gimona A, Hawkey CJ, TARGET Study Group: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364:665-674.
9. Lanas A, Perez-Aisa MA, Feu F, Ponce J, Saperas E, Santolaria S, Rodrigo L, Balanzo J, Bajador E, Almela P, Navarro JM, Carballo F, Castro M, Quintero E, Investigators of the Asociacion Espanola de Gastroenterologia (AEG): A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with non-steroidal anti-inflammatory drug use. Am J Gastroenterol 2005;100:1685-1693.
10. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS: Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. Celecoxib Long-Term Arthritis Safety Study. JAMA 2000;284:1247-1255.
11. Laine L, Maller ES, Yu C, Quan H, Simon T: Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2-selective inhibition: a double-blind trial. Gastroenterology 2004;127:395-402.
12. Skelly MM, Hawkey CJ: Dual COX inhibition and upper gastrointestinal damage. Curr Pharm Des 2003;9:2191-2195.
13. Mamdani M, Rochon PA, Juurlink DN, Kopp A, Anderson GM, Naglie G, Austin PC, Laupacis A: Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 2002;325:624.
14. Norgard B, Pedersen L, Johnsen SP, Tarone RE, McLaughlin JK, Friis S, Sorensen HT: COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study. Aliment Pharmacol Ther 2004;19:817-825.
15. Laine L, Connors LG, Reicin A, Hawkey CJ, Burgos-Vargas R, Schnitzer TJ, Yu K, Bombardier C: Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003;124:288-292.
16. Bjorkman D: Nonsteroidal anti-inflammatory drug-associated toxicity of the liver, lower gastrointestinal tract, and esophagus. Am J Med 1989;2:17S-21S.
17. Rossini FP, Pennazio M: Small-bowel endoscopy. Endoscopy 2002;34:13-20.
18. Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I: A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005;128:1172-1178.
19. Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI: Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs. N Engl J Med 1992;327:749-754.
20. Sigthorsson G, Tibble J, Hayllar J, Menzies I, Macpherson A, Moots R, Scott D, Gumpel MJ, Bjarnason I: Intestinal permeability and inflammation in patients on NSAIDs. Gut 1998;43:506-511.
21. Bjarnason I, Smethurst P, Macpherson A, Walker F, McElnay JC, Passmore AP, Menzies IS: Glucose and citrate reduce the permeability changes caused by indomethacin in humans. Gastroenterology 1992;102:1546-1550.
22. Bjarnason I, Williams P, Smethurst P, Peters TJ, Levi AJ: Effect of non-steroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small intestine. Gut 1986;27:1292-1297.
23. Smecuol E, Bai JC, Sugai E, Vázquez H, Niveloni S, Pedreira S, Maurino E, Meddings J: Acute gastrointestinal permeability responses to different nonsteroidal anti-inflammatory drugs. Gut 2001;49:650-655.
24. Tibble JA, Sigthorsson G, Foster R, Bjarnason I: Comparison of the intestinal toxicity of celecoxib, a selective COX-2 inhibitor, and indomethacin in the experimental rat. Scand J Gastroenterol 2000;35:802-807.
25. Bjarnason I, Zanelli G, Prouse P, Smethurst P, Smith T, Levi S, Gumpel MJ, Levi AJ: Blood and protein loss via small-intestinal inflammation induced by non-steroidal anti-inflammatory drugs. Lancet 1987;ii:711-714.
26. Poullis A, Foster R, Mendall MA, Fagerhol MK: Emerging role of calprotectin in gastroenterology. J Gastroenterol Hepatol 2003;18:756-762.
27. Tibble JA, Sigthorsson G, Foster R, Scott D, Fagerhol MK, Roseth A, Bjarnason I: High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut 1999;45:362-366.
28. Bjarnason I, Zanelli G, Smith T, Smethurst P, Price AB, Gumpel MJ, Levi AJ: The pathogenesis and consequence of non-steroidal anti-inflammatory drug induced small intestinal inflammation. Scand J Rheumatol 1987;22(suppl 64):55-62.
29. Morris AJ, Madhok R, Sturrock RD, Capell HA, Mackenzie JF: Enteroscopic diagnosis of small bowel ulceration in patients receiving non-steroidal anti-inflammatory drugs. Lancet 1991;337:520.
30. Teahon K, Bjarnason I: Comparison of leukocyte excretion and blood loss in inflammatory disease of the bowel. Gut 1993;34:1535-1538.
31. Etienney I, Beaugerie L, Viboud C, Flahault A: Non-steroidal anti-inflammatory drugs as a risk factor for acute diarrhoea: a case crossover study. Gut 2003;52:260-263.
32. Chutkan R, Toubia N: Effect of nonsteroidal anti-inflammatory drugs on the gastrointestinal tract: diagnosis by wireless capsule endoscopy. Gastrointest Endosc Clin N Am 2004;14:67-85.
33. Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S, Fort JG: Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005;3:133-141.
34. Halter F, Weber B, Huber T, Eigenmann F, Frey MP, Ruchti C: Diaphragm disease of the ascending colon. J Clin Gastroenterol 1993;16:74-80.
35. Lanas A, Sekar MC, Hirschowitz BI: Objective evidence of aspirin use in both ulcer and non-ulcer upper and lower gastrointestinal bleeding. Gastroenterology 1992;103:862-869.
36. Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R: Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology 1997;112:683-689.
37. Day TK: Intestinal perforation associated with osmotic slow release indomethacin capsules. Br Med J 1983;287:1671-1672.
38. Davies NM: Sustained release and enteric coated NSAIDs: are they really GI safe? J Pharm Pharm Sci 1999;2:5-14.
39. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, Isakson PC, Seibert K: Selective inhibition of inducible cyclooxygenase in vivo is anti-inflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994;91:3228-3232.
40. Yokota A, Taniguchi M, Takahira Y, Tanaka A, Takeuchi K: Rofecoxib produces intestinal but not gastric damage in the presence of a low dose of indomethacin in rats. J Pharmacol Exp Ther 2005;314:302-309.
41. Hunt RH, Bowen B, Mortensen ER, Simon TJ, James C, Cagliola A, Quan H, Bolognese JA: A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects. Am J Med 2000;109:201-206.
42. Sigthorsson G, Crane R, Simon T, Hoover M, Quan H, Bolognese J, Bjarnason I: COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double-blind crossover study comparing rofecoxib with placebo and indomethacin. Gut 2000;47:527-532.
43. Atherton C, Jones J, McKaig B, Bebb J, Cunliffe R, Burdsall J, Brough J, Stevenson D, Bonner J, Rordorf C, Scott G, Branson J, Hawkey CJ: Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: an integrated study. Clin Gastroenterol Hepatol 2004;2:113-120.
44. Shall AA, Thjodleifsson B, Murray FE, Kay E, Barry M, Sigthorsson G, Gudjonsson H, Oddsson E, Price AB, Fitzgerald DJ, Bjarnason I: Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. Gut 2001;48:339-346.
45. Hunt RH, Harper S, Callegari P, Yu C, Quan H, Evans J, James C, Bowen B, Rashid F: Complementary studies of the gastrointestinal safety of the cyclooxygenase-2-selective inhibitor etoricoxib. Aliment Pharmacol Ther 2003;17:201-210.
46. Burke TA, Zabinski RA, Pettitt D, Maniadakis N, Maurath CJ, Goldstein JL: A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis. Pharmacoeconomics 2001;19(suppl 1):33-47.
47. Mahadevan U, Loftus EV Jr, Tremaine WJ, Sandborn WJ: Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol 2002;97:910-914.
48. Cleland LG, James MJ, Stamp LK, Penglis PS: COX-2 inhibition and thrombotic tendency: a need for surveillance. Med J Aust 2001;175:214-217.
49. Boers M: NSAIDS and selective COX-2 inhibitors: competition between gastroprotection and cardioprotection. Lancet 2001;357:1222-1223.
50. Justice E, Carruthers DM: Cardiovascular risk and COX-2 inhibition in rheumatological practice. J Hum Hypertens 2005;19:1-5.
51. Catella-Lawson F, Crofford LJ: Cyclooxygenase inhibition and thrombogenicity. Am J Med 2001;110(suppl 3A):28S-32S.
52. Baigent C, Patrono C: Selective cyclooxygenase-2 inhibitors, aspirin, and cardiovascular disease: a reappraisal. Arthritis Rheum 2003;48:12-20.
53. Mukherjee D, Nissen SE, Topol RJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001;286:954-959.
54. Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, Gertz BJ: Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001;104:2280-2288.
55. White WB, Faich G, Whelton A, Maurath C, Ridge NJ, Verburg KM, Geis GS, Lefkowith JB: Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002;89:425-430.
56. Mamdani M, Rochon P, Juurlink DN, Anderson GM, Kopp A, Naglie G, Austin PC, Laupacis A: Effect of selective cyclooxygenase-2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003;163:481-486.
57. Shaya FT, Blume SW, Blanchette CM, Weir MR, Mullins CD: Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population. Arch Intern Med 2005;165:181-186.
58. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR: COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002;360:1071-1073.
59. Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J: Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004;109:2068-2073.
60. Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, Strom BL: Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005;142:157-164.
61. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA: Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase-2-selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005;365:475-481.
62. Lévesque LE, Brophy JM, Zhang B: The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005;142:481-489.
63. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M, Adenoma Prevention with Celecoxib (APC) Study Investigators: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-1080.
64. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM: Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005;352:1081-1091.
65. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA, Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-1102.
66. FDA Alert for Health Care Provider: Naproxen [http://www.fda.gov/cder/ drug/InfoSheets/HCP/Naproxen-hcp.pdf].
67. Shah AA, Thjodleifsson B, Murray FE, Kay E, Barry M, Sigthorsson G, Gudjonsson H, Oddsson E, Price AB, Fitzgerald DJ, Bjarnason I: Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. Gut 2001;48:339-346.
68. Knijff-Dutmer EA, Kalsbeek-Batenburg EM, Koerts J, van de Laar MA: Platelet function is inhibited by non-selective non-steroidal anti-inflammatory drugs but not by cyclooxygenase-2-selective inhibitors in patients with rheumatoid arthritis. Rheumatology (Oxford) 2002;41:458-461.
69. Rothschild BM: Comparative antiplatelet activity of COX1 NSAIDS versus aspirin, encompassing regimen simplification and gastroprotection: a call for a controlled study. Reumatismo 2004;56:89-93.
70. Capone ML, Tacconelli S, Sciulli MG, Grana M, Ricciotti E, Minuz P, Di Gregorio P, Merciaro G, Patrono C, Patrignani P: Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 2004;109:1468-1471.
71. Hippisley-Cox J, Coupland C: Risk of myocardial infarction in patients taking cyclooxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population-based nested case-control analysis. BMJ 2005;330:1366-1372.
72. Hudson M, Richard H, Pilote L: Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population-based study. BMJ 2005;330:1370-1375.
73. Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Norgard B, Friis S, Sorensen HT: Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 2005;165:978-984.
74. Brater DC: Anti-inflammatory agents and renal function. Semin Arthritis Rheum 2002;32(suppl 1):33-42.
75. Armstrong EP, Malone DC: The impact of nonsteroidal anti-inflammatory drugs on blood pressure, with an emphasis on newer agents. Clin Ther 2003;25:1-18.
76. Izzo JL, Levy D, Black HR: Importance of systolic blood pressure in older Americans. Clinical advisory statement. Hypertension 2000;35:1021-1024.
77. ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000;283:1967-1975.
78. Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM, SUCCESS VI Study Group: Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001;8:85-95.
79. Whelton A, White WB, Bello AE, Puma JA, Fort JG: Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or = 65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002;90:959-963.
80. Hawkey CJ: Cyclooxygenase inhibition: between the devil and the deep blue sea. Gut 2002;50(suppl 3):25-30.
81. Harley C, Wagner S: The prevalence of cardiorenal risk factors in patients prescribed non steroidal anti-inflammatory drugs: data from managed care. Clin Ther 2003;25:139-149.
82. FDA Public Health Advisory: FDA Announces Important Changes and Additional Warnings for COX-2-Selective and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) [http://www.fda.gov/cder/drug/advisory/COX2. htm].
83. EMEA/62838/2005 Public Statement - European Medicines Agency announces regulatory action on COX-2 inhibitors [http://www.emea.eu.int/htms/hotpress/ d6275705.htm].
84. Somasundaram S, Sigthorsson G, Simpson RJ, Watts J, Jacob M, Tavares IA, Rafi S, Roseth A, Foster R, Price AB, Wrigglesworth JM, Bjarnason I: Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID enteropathy in the rat. Aliment Pharmacol Ther 2000;14:639-650.
85. Davies NM, Jamali F: Pharmacological protection of NSAID-induced intestinal permeability in the rat: effect of tempo and metronidazole as potential free radical scavengers: Hum Exp Toxicol 1997;16:345-349.
86. Bjarnason I, Hayllar J, Macpherson AJ, Russell AS: Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993;104:1832-1847.
87. Bertrand V, Guimbaud R, Tulliez M, Mauprivez C, Sogni P, Couturier D, Giroud JP, Chaussade S, Chauvelot-Moachon L: Increase in tumour necrosis factor-α production linked to the toxicity of indomethacin for the rat small intestine. Br J Pharmacol 1998;124:1385-1394.
88. Stadnyk AW, Dollard C, Issekutz TB, Issekutz AC: Neutrophil migration into indomethacin induced rat small intestinal injury is CD11a/CD18 and CD11b/CD18 co-dependent. Gut 2002;50:629-635.
89. Appleyard CB, McCafferty DM, Tigley AW, Swain MG, Wallace JL: Tumour necrosis factor mediation of NSAID-induced gastric damage: role of leukocyte adherence. Am J Physiol 1996;270:G42-G48.
90. Reuter BK, Wallace JL: Phosphodiesterase inhibitors prevent NSAID enteropathy independently of effects on TNF-α release. Am J Physiol 1999;277:G847-G854.
91. Robert A, Asano T: Resistance of germ-free rats to indomethacin-induced intestinal lesions. Prostaglandins 1977;14:333-341.
92. Wax J, Clinger WA, Varner P, Bass P, Winder CV: Relationship of the enterohepatic cycle to ulcerogenesis in the rat small bowel with flufenamic acid. Gastroenterology 1970;58:772-780.
93. Reuter BK, Davies NM, Wallace JL: Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic recirculation. Gastroenterology 1997;112:109-117.
94. Langenbach R, Morham SG, Tiano HF, Loftin CD, Ghanayem BI, Chulada PC, Mahler JF, Lee CA, Goulding EH, Kluckman KD, Kim HS, Smithies O: Prostaglandin synthase-1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin induced gastric ulceration. Cell 1995;83:483-492.
95. Sigthorsson G, Simpson RJ, Walley M, Anthony A, Foster R, Hotz-Behoftsitz C, Palizban A, Pombo J, Watts J, Morham SG, Bjarnason I: COX-1 and 2, intestinal integrity, and pathogenes is of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology 2002;122:1913-1923.
96. Takeuchi K, Tanaka A, Ohno R, Yokota A: Role of COX inhibition in pathogenesis of NSAID-induced small intestinal damage. J Physiol Pharmacol 2003;54(suppl 4):165-182.
97. Houchen CW, Stenson WF, Cohn SM: Disruption of cyclooxygenase-1 gene results in an impaired response to radiation injury. Am J Physiol 2000;279:G858-G865.
98. Redfern JS, Feldman M: Role of endogenous prostaglandins in preventing gastrointestinal ulceration: induction of ulcers by antibodies to prostaglandins. Gastroenterology 1989;96:596-605.
99. Davies GR, Wilkie ME, Rampton DS: Effects of metronidazole and misoprostol on indomethacin-induced changes in intestinal permeability. Dig Dis Sci 1993;38:417-425.
100. 51Cr-EDTA in controls caused by naproxen is not prevented by cytoprotection. Arthritis Rheum 1998;31(suppl 1):R11.
101. Wallace JL, Del Soldato P: The therapeutic potential of NO-NSAIDs. Fundam Clin Pharmacol 2003;17:11-20.
102. Hawkey CJ, Jones JI, Atherton CT, Skelly MM, Bebb JR, Fagerholm U, Jonzon B, Karlsson P, Bjarnason IT: Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. Gut 2003;52:1537-1542.
103. Fiorucci S, Santucci L, Gresele P, Faccino RM, Del Soldato P, Morelli A: Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 2003;124:600-607.
104. Conforti A, Donini M, Brocco G, De Soldato P, Benoni G, Cuzzolin L: Acute anti-inflammatory activity and gastrointestinal tolerability of diclofenac and nitrofenac. Agents Actions 1993;40:176-180.
105. Saud B, Nandi J, Ong G, Finocchiaro S, Levine RA: Inhibition of TNF-α improves indomethacin-induced enteropathy in rats by modulating iNOS expression. Dig Dis Sci 2005:50:1677-1683.
106. Davies NM, Jamali F: Pharmacological protection of NSAID-induced intestinal permeability in the rat: effect of tempo and metronidazole as potential free radical scavengers. Hum Exp Toxicol 1997;16:345-349.
107. Banerjee AK, Peters TJ: Experimental non-steroidal anti-inflammatory drug-induced enteropathy in the rat: similarities to inflammatory bowel disease and effect of thromboxane synthetase inhibitors. Gut 1990;31:1358-1364.
108. Hagiwara M, Kataoka K, Arimochi H, Kuwahara T, Ohnishi Y: Role of unbalanced growth of Gram-negative bacteria in ileal ulcer formation in rats treated with a nonsteroidal anti-inflammatory drug. J Med Invest 2004;51:43-51.
109. Koga H, Aoyagi K, Matsumoto T, Iida M, Fujishima M: Experimental enteropathy in athymic and euthymic rats: synergistic role of lipopolysaccharide and indomethacin. Am J Physiol 1999;276:G576-G582.
110. Kinouchi T, Kataoka K, Bing SR, Nakayama H, Uejima M, Shimono K, Kuwahara T, Akimoto S, Hiraoka I, Ohnishi Y: Culture supernatants of Lactobacillus acidophilus and Bifidobacterium adolescentis repress ileal ulcer formation in rats treated with a nonsteroidal anti-inflammatory drug by suppressing unbalanced growth of aerobic bacteria and lipid peroxidation. Microbiol Immunol 1998;42:347-355.
111. Freeman CD, Klutman NE, Lamp KC: Metronidazole: a therapeutic review and update. Drugs 1997;54:679-708.
112. Bjarnason I, Smethurst P, Fenn CG, Lee CE, Menzies IS, Levi AJ: Misoprostol reduces indomethacin-induced changes in human small intestinal permeability. Dig Dis Sci 1989;34:407-411.
113. Bjarnason I, Hayllar J, Smethurst P, Price A, Gumpel MJ: Metronidazole reduces intestinal inflammation and blood loss in non-steroidal anti-inflammatory drug induced enteropathy. Gut 1992;33:1204-1208.
114. Leite AZ, Sipahi AM, Damiao AO, Coelho AM, Garcez AT, Machado MC, Buchpiguel CA, Lopasso FP, Lordello ML, Agostinho CL, Laudanna AA: Protective effect of metronidazole on uncoupling mitochondrial oxidative phosphorylation induced by NSAID: a new mechanism. Gut 2001;48:163-167.
115. Ganrot-Norlin K, Stalhandske T, Karlstrom R: Lack of anti-inflammatory activity of metronidazole. Acta Pharmacol Toxicol (Copenh) 1981;49:130-133.
116. Riordan SM, McIver CJ, Thomas DH, Duncombe VM, Bolin TD, Thomas MC: Luminal bacteria and small-intestinal permeability. Scand J Gastroenterol 1997;32:556-563.
117. Konaka A, Kato S, Tanaka A, Kunikata T, Korolkiewicz R, Takeuchi K: Roles of enterobacteria, nitric oxide and neutrophil in pathogenesis of indomethacin-induced small intestinal lesions in rats. Pharmacol Res 1999;40:517-524.
118. Müller M: Reductive activation of nitroimidazoles in anaerobic microorganisms. Biochem Pharmacol 1986;35:37-41.
119. Akamatsu H, Oguchi M, Nishijima S, Asada Y, Takahashi M, Ushijima T, Niwa Y: The inhibition of free radical generation by human neutrophils through the synergistic effects of metronidazole with palmitoleic acid: a possible mechanism of action of metronidazole in rosacea and acne. Arch Dermatol Res 1991;282:449-454.
120. Arndt H, Paltisch KD, Grisham MB, Granger DN: Metronidazole inhibits leukocyte-endothelial cell adhesion in rat mesenteric venules. Gastroenterology 1994;106:1271-1276.
121. Hayllar J, Smith T, Macpherson A, Price AB, Gumpel M, Bjarnason I: Nonsteroidal anti-inflammatory drug-induced small intestinal inflammation and blood loss. Effects of sulfasalazine and other disease-modifying anti-rheumatic drugs. Arthritis Rheum 1994;37:1146-1150.
122. Scarpignato C, Pelosini I: Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 2005;51(suppl 1):36-66.
123. Kadam UT, Jordan K, Croft PR: Clinical comorbidity in patients with osteoarthritis: a case-control study of general practice consulters in England and Wales. Ann Rheum Dis 2004;63:408-414.
124. Manetas M, O'Loughlin C, Kelemen K, Barkin JS: Multiple small-bowel diaphragms: a cause of obscure GI bleeding diagnosed by capsule endoscopy. Gastrointest Endosc 2004;60:848-851.
125. Troost FJ, Saris WH, Brummer RJ: Recombinant human lactoferrin ingestion attenuates indomethacin-induced enteropathy in vivo in healthy volunteers. Eur J Clin Nutr 2003;57:1579-1585.
126. Dial EJ, Dohrman AJ, Romero JJ, Lichtenberger LM: Recombinant human lactoferrin prevents NSAID-induced intestinal bleeding in rodents. J Pharm Pharmacol 2005;57:93-99.
127. Conneely OM: Anti-inflammatory activities of lactoferrin. J Am Coll Nutr 2001;20(suppl 5):389S-395S.
128. Lonnerdal B: Nutritional and physiologic significance of human milk proteins. Am J Clin Nutr 2003;77:1537S-1543S.
129. Liepke C, Adermann K, Raida M, Mägert HJ, Forssmann WG, Zucht HD: Human milk provides peptides highly stimulating the growth of bifidobacteria. Eur J Biochem 2002;269:712-718.
130. Nitromed: Nitric oxide-enhancing NSAIDs for inflammation [http://www.nitromed.com/pain_inflammation.asp].
131. Nitromed® Press Release: Merck and Nitro-Med advance first nitric oxide-enhancing COX-2 inhibitor into phase II clinical testing [http://www.nitromed.com/06_22_04.shtml].
132. NewsRx: Merck halts trial of lead candidate in nitric oxide-enhancing COX-2 inhibitors [http://www.newsrx.com/issue_article/Health-and-Medicine-Week/ 2004-10-25/102520043334665W.html].